Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,650 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A Proposed Brain-, Spine-, and Mental- Health Screening Methodology (NEUROSCREEN) for Healthcare Systems: Position of the Society for Brain Mapping and Therapeutics.
Nami M, Thatcher R, Kashou N, Lopes D, Lobo M, Bolanos JF, Morris K, Sadri M, Bustos T, Sanchez GE, Mohd-Yusof A, Fiallos J, Dye J, Guo X, Peatfield N, Asiryan M, Mayuku-Dore A, Krakauskaite S, Soler EP, Cramer SC, Besio WG, Berenyi A, Tripathi M, Hagedorn D, Ingemanson M, Gombosev M, Liker M, Salimpour Y, Mortazavi M, Braverman E, Prichep LS, Chopra D, Eliashiv DS, Hariri R, Tiwari A, Green K, Cormier J, Hussain N, Tarhan N, Sipple D, Roy M, Yu JS, Filler A, Chen M, Wheeler C, Ashford JW, Blum K, Zelinsky D, Yamamoto V, Kateb B. Nami M, et al. Among authors: green k. J Alzheimers Dis. 2022;86(1):21-42. doi: 10.3233/JAD-215240. J Alzheimers Dis. 2022. PMID: 35034899 Review.
Neuroscience20 (BRAIN20, SPINE20, and MENTAL20) Health Initiative: A Global Consortium Addressing the Human and Economic Burden of Brain, Spine, and Mental Disorders Through Neurotech Innovations and Policies.
Morris K, Nami M, Bolanos JF, Lobo MA, Sadri-Naini M, Fiallos J, Sanchez GE, Bustos T, Chintam N, Amaya M, Strand SE, Mayuku-Dore A, Sakibova I, Biso GMN, DeFilippis A, Bravo D, Tarhan N, Claussen C, Mercado A, Braun S, Yuge L, Okabe S, Taghizadeh-Hesary F, Kotliar K, Sadowsky C, Chandra PS, Tripathi M, Katsaros V, Mehling B, Noroozian M, Abbasioun K, Amirjamshidi A, Hossein-Zadeh GA, Naraghi F, Barzegar M, Asadi-Pooya AA, Sahab-Negah S, Sadeghian S, Fahnestock M, Dilbaz N, Hussain N, Mari Z, Thatcher RW, Sipple D, Sidhu K, Chopra D, Costa F, Spena G, Berger T, Zelinsky D, Wheeler CJ, Ashford JW, Schulte R, Nezami MA, Kloor H, Filler A, Eliashiv DS, Sinha D, DeSalles AAF, Sadanand V, Suchkov S, Green K, Metin B, Hariri R, Cormier J, Yamamoto V, Kateb B. Morris K, et al. Among authors: green k. J Alzheimers Dis. 2021;83(4):1563-1601. doi: 10.3233/JAD-215190. J Alzheimers Dis. 2021. PMID: 34487051 Review.
Phase 2A Proof-of-Concept Double-Blind, Randomized, Placebo-Controlled Trial of Nicotinamide in Early Alzheimer Disease.
Grill JD, Tam S, Thai G, Vides B, Pierce AL, Green K, Gillen DL, Teng E, Kremen S, Beigi M, Rissman RA, Léger GC, Balasubramanian A, Revta C, Morrison R, Jennings R, Pa J, Zhang J, Jin S, Messer K, Feldman HH. Grill JD, et al. Among authors: green k. Neurology. 2025 Jan 14;104(1):e210152. doi: 10.1212/WNL.0000000000210152. Epub 2024 Dec 13. Neurology. 2025. PMID: 39671543 Clinical Trial.
Bispecific antibodies targeting BCMA or GPRC5D are highly effective in relapsed myeloma after CAR T-cell therapy.
Merz M, Dima D, Hashmi H, Ahmed N, Stölzel F, Holderried TAW, Fenk R, Müller F, Tovar N, Oliver-Cáldes A, Rathje K, Davis JA, Fandrei D, Vucinic V, Kharboutli S, Baermann BN, Ayuk F, Platzbecker U, Albici AM, Schub N, Schmitz F, Shune L, Khouri J, Anwer F, Raza S, McGuirk J, Mahmoudjafari Z, Green K, Khandanpour C, Teichert M, Jeker B, Hoffmann M, Kröger N, von Tresckow B, de Larrea CF, Pabst T, Abdallah AO, Gagelmann N. Merz M, et al. Among authors: green k. Blood Cancer J. 2024 Dec 5;14(1):214. doi: 10.1038/s41408-024-01197-2. Blood Cancer J. 2024. PMID: 39632797 Free PMC article.
2,650 results